Pipeline

Positioning MIRA1a and Ketamir-2 for an initial IND application in 2024

MIRA1a Pre-Clinical IND Phase 1 Phase 2 Phase 3

MIRA1a

Anxiety & Cognitive Decline in early stage dementia patients

Pre-Clinical Phase complete
IND Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started

MIRA1a

Neuropathic Pain

Pre-Clinical Phase complete
IND Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started

Ketamir-2

Treatment Resistant Depression (TRD)

Pre-Clinical Phase in progress
IND Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started

Ketamir-2

Major Depressive Disorder with Suicidal Ideation (MDDSI)

Pre-Clinical Phase in progress
IND Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started

MIRA Pharmaceuticals Timeline

Pre-clinical work is underway and should be completed by Q4’24

Q1 2024

  • Metabolic Profiling
  • ˆMTD/7D DRF Rat
  • ˆMTD/7D DRF Dog

Q2 2024

  • Micronucleus Assay
  • *Cardiovascular Study Dog
  • **Respiratory Study Rat
  • ***hERG
  • Neurobehavioral Evaluation Rat

Q3 2024

  • Dog 28-day Toxicology
  • Rat 28-day Toxicology

Q4 2024

  • IND Submission

Q1 2025

  • Phase 1 (30 days post IND submission)

Q2 2025

Q3 2025

Q4 2025